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Summary.-The combined effect of bleomycin and the polyene antibiotic, penta-
mycin, upon the survival of EMT6 tumour cells has been studied both in vitro and
in vivo. During growth of the cells as a monolayer in vitro, avery marked potentiation
of bleomycin action is seen during the exponential and early plateau phases of
growth, but little potentiation occurs in late plateau phase. The effect of exposing
the cells to the two drugs consecutively in either order is greater than if the two
agents are used at the same time. In vivo, it does not appear that pentamycin can
greatly increase the cytocidal effect of bleomycin.
IT HAS recently been demonstrated
that the action of certain cancer chemo-
therapeutic agents may be potentiated
by their combination with substances
categorized as polyene antibiotics. The
effect of 1,3 Bis(2-chloroethyl)-l-nitroso-
urea (BCNU) against the L1210 lympho-
ma is greatly increased if amphotericin B
is administered at the same time (Medoff et
at., 1974), and the effect of 5-fluorouracil
in tissue culture has also been found to
be increased by this agent (Kuwano et
al., 1973). Whereas no synergism could
be found between bleomycin and ampho-
tericin B, the inhibition of DNA, RNA
and protein synthesis in vitro by bleo-
mycin has been shown to be increased
in the presence of pentamycin, an anti-
fungal polyene antibiotic (Nakashima et
al., 1974).
In this paper experiments are described
which were designed to investigate the
effect of bleomycin and pentamycin in
combination on cell survival both in
vitro and in an experimental tuimouir
system in vivo.
AIATERIALS AND METHODS
Bleomycin (BLM) Mwas kindly supplied
by Lundbeck Limited. Foro use in vitro,
the drug was added to tissue culture flasks
in a volume of between 005 and 0-2 ml of
complete medium. For in vivo studies, a
dose of 4 mg/kg was administered i.p. in
0 5 ml of sterile Hanks' solution. Penta-
mycin (PENT) was a gift from Professor H.
Umezawa. For use in vitro, the drug was
dissolved in dimethyl sulphoxide and added
in a volume of 0-1 ml. For in vivo adminis-
tration, PENT was suspended in 05%
carboxymethyl cellulose in Hanks' solution
and injected i.p. in a volume of 0-5 ml.
Our in vitro cell line EMT/6/M/CC and
the handling procedures used in our labora-
tory have been described elsewhere (Twenty-
man and Bleehen, 1975a). The cell pro-
liferation kinetics show marked changes
as the age of the culture increases and three
distinct phases of growth can be identified
(Twentyman et al., 1975). We have named
the three phases, " exponential ", early
plateau" and ' late plateau".
Drugs were added directly to the medium
in which cells wNere growing, and at the
end of the exposure period, the medium was
removed and cultures rinsed with complete
medium. Cells were then trypsinized from
the surface, counted, diluted and plated as
previously described (Twentyman and Blee-
hen, 1975a). Colonies containing more than
50 cells Aere counted 9-10 days later.
The EMT6 tumour system in which
tumours growing in Balb/C mice are treatedP. R. TWENTYMAN
in vivo and cell survival assayed by plating in
vitro has been previously described (Twenty-
man and Bleehen, 1974, 1975b). In the
current series of experiments tumours of
the subline EMT6/VJ/AC were initiated by
the intradermal inoculation of 4 x 104 cells
at Day 0. Tumours were used on Day 9-10
when they had reached a size of around
150 mm3. In one series of experiments
cells were taken from tumours treated with
BLM in vivo, and the cell suspension was
divided into halves. PENT (5 ,ug/ml) was
added to one half and DMSO to the other.
Both suspensions were then mixed at 37°C
for 30 min before being spun down, rinsed
twice with medium, counted and plated
out.
RESULTS
Pentamycin dose-response
The effect of incubating exponential
phase cells with BLM (20 ,tg/ml) and
various doses of PENT together for
a period of 1 h is shown in Fig. 1. Two
separate experiments are shown. At 1
,ug/ml of PENT the potentiation is
relatively small, but by a dose of 3 ,ug/ml
virtually the whole effect is seen. Little
further effect is brought about by increas-
ing the PENT dose to 10 ,ug/ml. No
significant cell killing was caused by
PENT alone at any dose level.
Bleomycin dose-response
In all subsequent experiments a PENT
dose of 5 ,ag/ml was used. The effect
of I h exposure of exponential phase
cells to this dose of PENT together with
various doses of BLM is seen in Fig. 2.
A very clear potentiation is seen for all
doses of BLM. At 30 ,ag/ml, the poten-
tiation is by a factor of nearly 103.
The BLM/PENT dose response curve
has the same biphasic shape that has
been widely observed for BLM alone in
various cell lines during exponential
growth (Terasima et al., 1972; Twentyman
and Bleehen, 1975a). In early plateau
phase the potentiation is rather less
than in exponential phase, with a factor
of 100 x at 30 ,ag/ml. The shape of the
curve is still biphasic. As the cells
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FIG. 1. Change in surviving fraction of
exponential phase EMT6 cells exposed to
BLM (20 ,ug/ml) for 1 h with dose of PENT
present simultaneously. Circles and tri-
angles show 2 separate experiments. Error
bars indicate ±2 standard errors based
on the total colony count on groups of 4
replicate dishes.
progress into late plateau phase the very
marked potentiation is lost. In accord-
ance with our previous observation
(Twentyman and Bleehen, 1975a) the
sensitivity to BLM alone during late
plateau was rather greater than seen in
exponential phase, but it appears that
little additional killing can be brought
about by the addition of PENT, the
potentiation at 30 ,ug/ml being only about
2-3 x.
Repair of " potentially lethal damage"
The effect of delayed subculture fol-
lowing 1 h exposure of cells to BLM
alone or to a combination of BLM and
460SURVIVAL OF EMT6 MOUSE TUMOUR CELLS IN VITRO AND IN VIVO
6210
FIG.
expc
of
alon
rors
com
expE
0
I 0 I _
EXPONENTIAL
I
0
'0
the zero time surviving fraction was
lowest. Following combination treat-
ment, an increase in surviving fraction
was again seen with delayed subculture
at all phases. The range of surviving
fraction ratios was generally similar to
that seen for BLM alone, and again
the highest surviving fraction ratio was
seen where the initial surviving fraction
was lowest.
Combination timing
O\ 0 0 The results of 2 experiments where
-_ o the timing ofBLM and PENT administra-
tion was varied are shown in Fig. 3.
° 0 ~ -8 ° In both experiments, consecutive expo-
sure to the two drugs in either order
-~_ produced greater cell killing than simul-
0 taneous exposure. With a gap of 2 h
10 20 30 a 60 between exposures to the two drugs, the
BLM (yg/ml) cell killing was approximately as great
as that produced by simultaneous ex-
2. Change in surviving fraction of as agred
by angradual onential phase EMT6 cells with dose posure. With a greater gap, a gradual
BLM for 1 h exposure. *-BLM reduction in the killing effect was seen, e, O BLM + PENT (5 ug/ml). Er- although a clear potentiation still existed
of individual determinations are small with a gap of 6 h, again irrespective pared with spread of results between ofth order ofadiitation ofte two
eriments. of the order of administration of the two
drugs.
PENT simultaneously is shown in Table
I. For cells treated with BLM alone a
considerable increase in surviving fraction
was seen at all phases. In general, the
surviving fraction ratio was highest when
BLM in vivo/PENT in vitro
The results of 2 experiments in which
cell suspensions were prepared from tu-
mours and exposed in vitro to PENT for
TABLE I. Effect of Delayed Subculture on Surviving Fraction of Cells Exposed In Vitro
to BLM Alone or BLM and PENT in Combination
BLM alone
Experiment
no. SF SFR(4)
0-17 3-8
0-59 0-8
0-14 2-2
0-42 1-2
0-37 1-8
0-16 2-8
BLM + PENT
SF SFR(4)
0-0025 1-2
0*0032 2 - 6
0-00053 5-1
0-0072 7 - 6
0-0131 6-3
0 0043 3-5
Late plateau 1 0 043 7-0 0 30
2 0-230 1-9 0-40
3 0-066 6-7 0-044
SF = Surviving fraction for immediate subculture
SFR(4) Surviving fraction for 4 h subculture delay Surviving fraction for immediate subculture
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FIG. 3. Change in surviving fraction of
EMT6 cells in exponential phase exposed
to BLM (B) and PENT (P) each for 1 h
with various intervals between exposures.
" Together " means simultaneous expo-
sure. Zero interval indicates one drug
followed immediately by the other. Circles
and triangles show 2 separate experiments.
Error bars indicate + 2 standard errors
based on the total colony count on groups
of 4 replicate dishes.
30 min are shown in Table II. The
tumours themselves were excised from
mice at various times after BLM ad-
ministration. It may be seen that sig-
nificant reduction in surviving fraction
was produced especially for tumours
removed at 30 min and 2 h after BLM
administration. The reduction for tu-
mours taken at 6 h after BLM was
however much less.
BLM + PENT in vivo
Results of experiments in which the
two drugs were each administered to
tumour-bearing mice are shown in Table
III. The dose of PENT used was 20
mg/kg. The range of values obtained
for the ratio of effect with PENT to
effect without PENT was wide, but
within the normal range seen for this
type of assay. The initial effect of
BLM (at 30 min) was of the same order
of magnitude in the presence or absence
of PENT, and the large recovery seen
with delayed subculture from 30 min
to 6 h still occurred. It did not appear
that PENT alone is very cytotoxic to
the tumour cells in vivo even at this
very high dose level, i.e. in excess of the
LD50.
DISCUSSION
It does not appear likely from these
results that the combination of BLM
and PENT will be clinically useful in
tumour therapy. Firstly, PENT itself
is highly toxic and also insoluble in
water or alcohol with subsequent problems
of administration. Secondly, both the
initial response of the tumour cells to
TABLE II.-Effect of 30 mmn Incubation with Pentamycin on Surviving Fraction of Cells
Taken from Solid EMT6 Tumours at Various Times after BLM Administration
in Vivo
Surviving fractions
Experiment Control
A -PENT +PENT
1-0 0.99
+/-=0 99
B -PENT =PENT
1.0 0-84
+/-=0*84
30 min after BLM 2 h after BLM
-PENT +PENT -PENT +PENT
3-45x O-3 1-07x O-3 6 - 34 x 10-2 1 01 x 10-3
+/-=0-31 +/-=0 16
-PENT +PENT
5-6x 10-3 1-3x 10-3
+/-=0-23
-PENT +PENT
2-0x 10-2 8-2x 10-3
+/-=0-41
6 h after BLM
-PENT +PENT
0-72 0-44
+/-=0-61
-PENT +PENT
0-78 0-62
+±-=0*80
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TABLE III.-Effect of BLM + PENT in Vivo upon EMT6 Solid Tumours
Surviving fractions
, ~~~~~~~~~~~~~AE
30 min after
Experiment BLM
A -PENT +PENT
0 0020 0-0012
+/- =0-60
B -PENT +-PENT
0-0013 0-0015
+!- =1-14
C -PENT +-PENT
0 00096 0 0030
+/- =3-1
2 h after
BLM
-PENT +PENT
0-018 0-024
+1-=1-33
-PENT +PENT
0-029 0-017
+/-=058
6 h after
BLM
-PENT +PENT
0 30 0-14
+/- =047
-PENT +PENT
0-20 0-37
+/- =1-85
-PENT
0-26
+l
PENT alone PENT alone
2h 6h
0 75 0 58
0-84 0-83
+-PENT
0-26
1*0
BLM and their subsequent recovery do
not appear to be greatly influenced by
PENT. One possible reason for this is
that the drug does not get to the tumour
cells following this mode of administra-
tion. If this is the case, however, it
seems likely that the non-access is absolute
rather than dependent upon a particular
timing of the combination. Our in vitro
results indicate that exposure of cells to
PENT within the period of several hours
each side of the BLM exposure can cause
potentiation, and hence the actual timing
should not be too important in vivo.
The response of tumour cells treated
in vitro following preparation of suspen-
sion is instructive in this respect in that
only limited potentiation is produced in
a situation where access of PENT to
the cells is without doubt. It appears
therefore that at least a large proportion
of the total population of tumour cells
react to the drug combination in the
same way as late plateau phase cells in
vitro.
The idea that PENT acts by increasing
the amount of BLM which penetrates
into the cell (Nakashima et al., 1974)
may well explain our findings. It has
been reported by Fujimoto (1974) that
ascites tumour cells exposed to 14C
BLM showed the label absorbed to the
cell membrane at 2 h after drug adminis-
tration with subsequent movement of the
label to the nuclear membrane by 4 h.
It seems possible, therefore, that cells
exposed to PENT undergo some change
in the membrane which allows more
penetration of BLM. If cells are exposed
to PENT after BLM then BLM which
is attached in some way to the cell
membrane and which normally would
be harmlessly released at some later
time is allowed to penetrate the mem-
brane.
If the concept that PENT acts by
altering membrane permeability is correct,
then our results imply that the relative
response to BLM alone shown by cells
in various growth phases is highly de-
pendent upon the state of the membrane
during these phases, and that the cell
membrane is a highly resistant barrier
to BLM at all growth phases in vitro.
Carried further, it is also possible that
the " repair ofpotentially lethal damage "
phenomenon could be accounted for in
terms of membrane permeability. It
would be necessary to postulate that
during the subculture procedure, or else
during some process occurring shortly
afterwards, BLM is allowed to pass
from its membrane-absorbed site into
the cell where cytotoxicity occurs. Cells
left without subculture would release the
BLM from the membrane into the extra-
cellularfluidwithoutcytotoxicityoccurring.
We are intending to investigate these
possibilities in our laboratory using
labelled BLM.
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